Filing Details

Accession Number:
0001209191-12-053796
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-11-19 16:35:52
Reporting Period:
2012-11-15
Filing Date:
2012-11-19
Accepted Time:
2012-11-19 16:35:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1349077 Lisa Kelly C/O Vertex Pharmaceuticals Incorporated
130 Waverly St.
Cambridge MA 02139
Svp, Human Resources No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2012-11-15 355 $40.59 17,249 No 4 S Direct
Common Stock Disposition 2012-11-16 2,033 $41.28 15,216 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,959 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $40.59 (range $40.34 to $41.23).
  3. Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $41.28 (range $41.01 to $41.82).